Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer

Re-epithelialization and immune cell behaviour in an ex vivo human skin model

(2020) Ana Rakita et al.   Scientific Reports

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors

(2020) Paul Savage et al.   Communications Biology

Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene

(2019) Suvimol Niyomnaitham et al.   PeerJ

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment

(2019) Ana C. Garrido-Castro et al.   Cancer Discovery

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model

(2019) Margarite D. Matossian et al.   BMC CANCER

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

(2019) Gloria V. Echeverria et al.   Science Translational Medicine

Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer

(2018) Tia H. Turner et al.   BREAST CANCER RESEARCH AND TREATMENT

High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer

(2018) Gloria V. Echeverria et al.   Nature Communications

KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells

(2017) Meng Jiang et al.   Oncotarget

Patient-derived xenograft (PDX) models in basic and translational breast cancer research

(2016) Lacey E. Dobrolecki et al.   CANCER AND METASTASIS REVIEWS

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

(2016) Alejandra Bruna et al.   CELL

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

(2016) Marc Hafner et al.   NATURE METHODS

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

(2016) Bernard Pereira et al.   Nature Communications

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts

(2015) I Lohse et al.   BRITISH JOURNAL OF CANCER

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset

(2015) B. Seashore-Ludlow et al.   Cancer Discovery

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

(2015) Zachary C. Dobbin et al.   Oncotarget

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Computational analysis of image-based drug profiling predicts synergistic drug combinations: Applications in triple-negative breast cancer

(2014) Miriam B. Brandl et al.   Molecular Oncology

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution

(2014) Peter Eirew et al.   NATURE

PyClone: statistical inference of clonal population structure in cancer

(2014) Andrew Roth et al.   NATURE METHODS

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Xenome--a tool for classifying reads from xenograft samples

(2012) T. Conway et al.   BIOINFORMATICS

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

(2012) Cynthia X. Ma et al.   JOURNAL OF CLINICAL INVESTIGATION

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

(2010) Kyle D. Holen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY